Leads to Development opens new offices in London and Lyon
Demand for non-clinical development support drives expansion
French company Leads To Development (L2D), a Paris-based specialist in the non-clinical development of novel therapeutics, is opening new offices in London in the UK and Lyon in France, as demand for its non-clinical development services continues to increase.
L2D is a pioneering business created to manage the non-clinical aspects of development projects, allowing biotech and pharmaceutical companies to bring in expertise as and when needed without having to build additional headcount and infrastructure.
All non-clinical development activities can be outsourced to L2D, which will manage part, or all, of the therapeutic programme from development plan design and writing through to the submission of the clinical trial application.
Non-clinical development encompasses all development activities required to be able to submit a clinical trial application, whatever the phase, including preclinical, as well as all the non-clinical aspects of phase I, II and III clinical trials. To complement these activities, L2D also provides business and strategic advice (including due diligence) to investors, biotechs, and pharmas.
‘We’ve seen substantial demand and uptake of our services across Europe. The UK and France are important markets for us and opening satellite offices in London and Lyon is an important step in L2D’s development,’ said Dr Jonathan Kearsey, founder and director of L2D.
‘The London office is based at the London Bio-science Innovation Centre and will allow biotech companies in the London, Oxford and Cambridge triangle to have faster and easier access to our expertise. Lyon has also shown itself to be an area of growth with great future potential and having an office at the centre of the Lyonbiopôle (Rhone–Alps) cluster will further enhance our client service offering.’
